Emre Koca, MD
Hematology & Oncology · Medford, ORNPI 1508271701
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $976 of the $1,102 with a category attached, or 88.6%. It is spread thinly across 23 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $478 and has fallen 74.4% since, to $123 in 2025.
Across 48 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$129
- E.r. Squibb & Sons, L.L.C.$128
- EUSA Pharma (US) LLC$108
- Lilly USA, LLC$94
- Amgen$78
- Pfizer$65
- plus $501 from 17 others
Across 6 payments — averaging $18,345 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$110K
What the payments were for
- Food & beverage$97689%
- Education$12611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $129 |
| E.r. Squibb & Sons, L.L.C. | 3 | $128 |
| EUSA Pharma (US) LLC | 1 | $108 |
| Lilly USA, LLC | 2 | $94 |
| Amgen | 3 | $78 |
| Pfizer | 5 | $65 |
| Genentech USA, Inc. | 3 | $57 |
| Eisai Inc. | 2 | $56 |
| Bristol Myers Squibb | 2 | $41 |
| Astellas Pharma US Inc | 2 | $36 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Rigel Pharmaceuticals, Inc. | 2 | $32 |
| Incyte Corporation | 2 | $32 |
| Gilead(2 entities) | 2 | $31 |
| Agios Pharmaceuticals, Inc. | 2 | $29 |
| Array Biopharma Inc | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Smith+Nephew | 1 | $18 |
| AbbVie | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sylvant$108
How this compares
$1,102 in reported general payments places this provider in the 55th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 14 | $436,443 |
| CalquenceAcalabrutinib Maleate | 22 | $299,490 |
| XtandiEnzalutamide | 21 | $297,101 |
| BrukinsaZanubrutinib | 29 | $261,666 |
| VerzenioAbemaciclib | 11 | $107,123 |
| Abiraterone Acetate | 29 | $61,484 |
| EliquisApixaban | 62 | $42,368 |
| Anastrozole | 215 | $2,853 |
| Exemestane | 47 | $2,520 |
| Tamoxifen Citrate | 110 | $1,298 |
| Oxycodone Hcl | 61 | $1,154 |
| Hydroxyurea | 27 | $1,065 |
| Ondansetron OdtOndansetron | 20 | $767 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 30 | $688 |
| Letrozole | 51 | $671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $32 | $436,44314 claims |
| Astellas Pharma US IncXtandi | $36 | $297,10121 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $94 | $107,30933 claims |
| PfizerEliquis | $65 | $42,36862 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $33 | $39949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Medford
- Ashish DwaryMedford$36K
- Mujahid RizviMedford$11K
- Sara MatarMedford$2K
- Aleksandra SanderMedford$1K
- Hidong KimMedford$1K
- Sandra TaylorMedford$1K
- Pragathi BalakrishnaMedford$985
- Tariq KhreisMedford$847
- Alison SavageMedford$730
- Brett PoissonMedford$709
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.